Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome
Abstract Background Critically ill patients with coronavirus disease 2019 (COVID-19) have a profound hypercoagulable state and often develop coagulopathy which leads to organ failure and death. Because of a prolonged activated partial-thromboplastin time (aPTT), a relationship with anti-phospholipid antibodies (aPL) has been proposed, but results are controversial. Functional assays for aPL (i.e., lupus anticoagulant) can be influenced by concomitant anticoagulation and/or high levels of C reactive protein. The presence of anti-cardiolipin (aCL), anti-beta2-glycoprotein I (anti-β2GPI) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies was not investigated systematically. Epitope specificity of anti-β2GPI antibodies was not reported.Objective To evaluate the prevalence and the clinical association of aPL in a large cohort of COVID-19 patients, and to characterize the epitope specificity of anti-β2GPI antibodies.Methods ELISA and chemiluminescence assays were used to test 122 sera of patients suffering from severe COVID-19. Of them, 16 displayed major thrombotic events.Results Anti-β2GPI IgG/IgA/IgM were the most frequent in 15.6/6.6/9.0% of patients, while aCL IgG/IgM were detected in 5.7/6.6% by ELISA. Comparable values were found by chemiluminescence. aPS/PT IgG/IgM were detectable in 2.5 and 9.8% by ELISA. No association between thrombosis and aPL was found. Reactivity against domain 1 and 4-5 of β2GPI was limited to 3/58 (5.2%) tested sera for each domain and did not correlate with aCL/anti-β2GPI nor with thrombosis.Conclusions aPL show a low prevalence in COVID-19 patients and are not associated with major thrombotic events. aPL in COVID-19 patients are mainly directed against β2GPI but display an epitope specificity different from antibodies in antiphospholipid syndrome..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
bioRxiv.org - (2021) vom: 03. Feb. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Borghi, Maria Orietta [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1101/2020.06.17.20134114 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI018179541 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI018179541 | ||
| 003 | DE-627 | ||
| 005 | 20230429100626.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200622s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.06.17.20134114 |2 doi | |
| 035 | |a (DE-627)XBI018179541 | ||
| 035 | |a (DE-599)biorXiv10.1101/2020.06.17.20134114 | ||
| 035 | |a (biorXiv)10.1101/2020.06.17.20134114 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Borghi, Maria Orietta |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background Critically ill patients with coronavirus disease 2019 (COVID-19) have a profound hypercoagulable state and often develop coagulopathy which leads to organ failure and death. Because of a prolonged activated partial-thromboplastin time (aPTT), a relationship with anti-phospholipid antibodies (aPL) has been proposed, but results are controversial. Functional assays for aPL (i.e., lupus anticoagulant) can be influenced by concomitant anticoagulation and/or high levels of C reactive protein. The presence of anti-cardiolipin (aCL), anti-beta2-glycoprotein I (anti-β2GPI) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies was not investigated systematically. Epitope specificity of anti-β2GPI antibodies was not reported.Objective To evaluate the prevalence and the clinical association of aPL in a large cohort of COVID-19 patients, and to characterize the epitope specificity of anti-β2GPI antibodies.Methods ELISA and chemiluminescence assays were used to test 122 sera of patients suffering from severe COVID-19. Of them, 16 displayed major thrombotic events.Results Anti-β2GPI IgG/IgA/IgM were the most frequent in 15.6/6.6/9.0% of patients, while aCL IgG/IgM were detected in 5.7/6.6% by ELISA. Comparable values were found by chemiluminescence. aPS/PT IgG/IgM were detectable in 2.5 and 9.8% by ELISA. No association between thrombosis and aPL was found. Reactivity against domain 1 and 4-5 of β2GPI was limited to 3/58 (5.2%) tested sera for each domain and did not correlate with aCL/anti-β2GPI nor with thrombosis.Conclusions aPL show a low prevalence in COVID-19 patients and are not associated with major thrombotic events. aPL in COVID-19 patients are mainly directed against β2GPI but display an epitope specificity different from antibodies in antiphospholipid syndrome. | ||
| 700 | 1 | |a Beltagy, Asmaa |e verfasserin |4 aut | |
| 700 | 1 | |a Garrafa, Emirena |e verfasserin |4 aut | |
| 700 | 1 | |a Curreli, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Cecchini, Germana |e verfasserin |4 aut | |
| 700 | 1 | |a Bodio, Caterina |e verfasserin |4 aut | |
| 700 | 1 | |a Grossi, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Blengino, Simonetta |e verfasserin |4 aut | |
| 700 | 1 | |a Tincani, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Franceschini, Franco |e verfasserin |4 aut | |
| 700 | 1 | |a Andreoli, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Lazzaroni, Maria Grazia |e verfasserin |4 aut | |
| 700 | 1 | |a Piantoni, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Masneri, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Crisafulli, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Brugnoni, Duilio |e verfasserin |4 aut | |
| 700 | 1 | |a Muiesan, Maria Lorenza |e verfasserin |4 aut | |
| 700 | 1 | |a Salvetti, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Parati, Gianfranco |e verfasserin |4 aut | |
| 700 | 1 | |a Torresani, Erminio |e verfasserin |4 aut | |
| 700 | 1 | |a Mahler, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Heilbron, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Pregnolato, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Pengo, Martino |e verfasserin |4 aut | |
| 700 | 1 | |a Tedesco, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Pozzi, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Meroni, Pier Luigi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 03. Feb. |
| 773 | 1 | 8 | |g year:2021 |g day:03 |g month:02 |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fimmu.2020.584241 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.06.17.20134114 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 03 |c 02 | ||
| 953 | |2 045F |a 570 | ||